Lantern Pharma (LTRN) Competitors

Lantern Pharma (NASDAQ:LTRN) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Is LTRN or PRME more profitable?

Lantern Pharma's return on equity of -56.91% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-56.91%	-51.17%
Prime Medicine	N/A	-107.87%	-74.97%

Does the media prefer LTRN or PRME?

In the previous week, Prime Medicine had 10 more articles in the media than Lantern Pharma. MarketBeat recorded 17 mentions for Prime Medicine and 7 mentions for Lantern Pharma. Lantern Pharma's average media sentiment score of 0.50 beat Prime Medicine's score of 0.07 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prime Medicine	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility & risk, LTRN or PRME?

Lantern Pharma has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.

Do analysts rate LTRN or PRME?

Lantern Pharma currently has a consensus price target of $25.00, suggesting a potential upside of 681.25%. Prime Medicine has a consensus price target of $11.80, suggesting a potential upside of 948.89%. Given Prime Medicine's higher possible upside, analysts clearly believe Prime Medicine is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Prime Medicine	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Which has better earnings & valuation, LTRN or PRME?

Lantern Pharma has higher earnings, but lower revenue than Prime Medicine. Lantern Pharma is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$15.96M	-$1.84	-1.74
Prime Medicine	$3.85M	38.41	-$198.13M	-$1.61	-0.70

Do institutionals and insiders hold more shares of LTRN or PRME?

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 7.3% of Lantern Pharma shares are held by insiders. Comparatively, 23.5% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the MarketBeat Community favor LTRN or PRME?

Prime Medicine received 17 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 76.47% of users gave Lantern Pharma an outperform vote while only 65.22% of users gave Prime Medicine an outperform vote.

Company	Underperform	Outperform
Lantern Pharma	Outperform Votes 13 76.47%	Underperform Votes 4 23.53%
Prime Medicine	Outperform Votes 30 65.22%	Underperform Votes 16 34.78%

Summary

Prime Medicine beats Lantern Pharma on 11 of the 17 factors compared between the two stocks.